Mixed-Methods Approach: Impact of Clinical Consenter Diversity on Clinical Trials Enrollment.

BACKGROUND

Clinical trials should benefit all people. Consequently, the National Cancer Institute expects cancer centers to accrue individuals to clinical trials in proportion to the cancer burden experienced by populations that live in their respective catchment areas; unfortunately, many cancer centers fail to meet this expectation. The person who gives consent for individuals in clinical trials frequently has significant contact with potential trial participants. We hypothesized that the race, ethnicity, and language of the consenter may have an important bearing on whether an individual chooses to participate in a clinical trial.

METHODS

We used mixed methods to investigate the impact of the socio-cultural background of the consenter on the decision of a potential research subject to participate in a clinical trial. Between 01/2018 and 02/2020, 205 women were approached in the sequential order they appeared in our breast clinic; of the 181 participants who agreed to complete the survey questionnaire, 94 (52%) were Northern European, non-Hispanic White (NE White), and 87 (48%) were Women-of-Color (WOC); this category includes participants who self-identified as Asian, Black, Hispanic/Latina, or Native American.

RESULTS

There were statistically significant differences according to the importance of the consenter's characteristics in the decision to enroll or decline participation in the BCT. No NE White enroller (0%, = 0) reported that consenter race was important versus 11% ( = 9) of WOC enrollers ( = 0.0009). Similarly, none of the NE White enrollers rated the consenter "looking like people in my community" as important versus 12% ( = 10) of the WOC enrollers ( = 0.0004).

CONCLUSIONS

We find that consenter race and ethnicity are important for clinical trial diversity. Larger studies are needed to evaluate the generalizability of this finding.